These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 34374773)

  • 61. Live vaccine against measles, mumps, and rubella and the risk of hospital admissions for nontargeted infections.
    Sørup S; Benn CS; Poulsen A; Krause TG; Aaby P; Ravn H
    JAMA; 2014 Feb; 311(8):826-35. PubMed ID: 24570246
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Missed opportunities for simultaneous administration of the fourth dose of DTaP among children in the United States.
    Zhao Z; Smith PJ; Hill HA
    Vaccine; 2017 May; 35(24):3191-3195. PubMed ID: 28479179
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Immunogenicity and Safety of Monovalent Acellular Pertussis Vaccine at Birth: A Randomized Clinical Trial.
    Wood N; Nolan T; Marshall H; Richmond P; Gibbs E; Perrett K; McIntyre P
    JAMA Pediatr; 2018 Nov; 172(11):1045-1052. PubMed ID: 30208475
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines.
    Rennels MB; Deloria MA; Pichichero ME; Losonsky GA; Englund JA; Meade BD; Anderson EL; Steinhoff MC; Edwards KM
    Pediatrics; 2000 Jan; 105(1):e12. PubMed ID: 10617749
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Timeliness of DTaP-IPV-Hib Vaccination and Development of Atopic Dermatitis Between 4 Months and 1 Year of Age-Register-Based Cohort Study.
    Gehrt L; Rieckmann A; Kiraly N; Jensen AKG; Aaby P; Benn CS; Sørup S
    J Allergy Clin Immunol Pract; 2021 Apr; 9(4):1520-1528.e8. PubMed ID: 33011301
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Four and one-half-year follow-up of the effectiveness of diphtheria-tetanus toxoids-acellular pertussis/Haemophilus influenzae type b and diphtheria-tetanus toxoids-acellular pertussis-inactivated poliovirus/H. influenzae type b combination vaccines in Germany.
    Kalies H; Verstraeten T; Grote V; Meyer N; Siedler A; Schmitt HJ; Breuer T; Moulton LH; von Kries R;
    Pediatr Infect Dis J; 2004 Oct; 23(10):944-50. PubMed ID: 15602195
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Comparative Efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure. Pertussis Vaccine Study Group.
    Heininger U; Cherry JD; Stehr K; Schmitt-Grohé S; Uberall M; Laussucq S; Eckhardt T; Meyer M; Gornbein J
    Pediatrics; 1998 Sep; 102(3 Pt 1):546-53. PubMed ID: 9738175
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Safety and immunogenicity of combined diphtheria-tetanus-pertussis (whole cell and acellular)-Haemophilus influenzae-b conjugate vaccines administered to Indonesian children.
    Richie E; Punjabi NH; Harjanto SJ; Wangsasaputral F; Sukandar M; Supriatman M; Simanjuntak CH; Que JU; Cryz SJ
    Vaccine; 1999 Mar; 17(11-12):1384-93. PubMed ID: 10195774
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Estimates of pertussis vaccine effectiveness in United States air force pediatric dependents.
    Wolff G; Bell M; Escobar J; Ruiz S
    Vaccine; 2015 Jun; 33(28):3228-33. PubMed ID: 25957071
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea.
    Lee SY; Hwang HS; Kim JH; Kim HH; Lee HS; Chung EH; Park SE; Ma SH; Chang JK; Guitton F; Ortiz E; Kang JH
    Vaccine; 2011 Feb; 29(8):1551-7. PubMed ID: 21215828
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Pertussis vaccination: acellular pertussis vaccine for reinforcing and booster use--supplementary ACIP statement. Recommendations of the Immunization Practices Advisory Committee (ACIP).
    MMWR Recomm Rep; 1992 Feb; 41(RR-1):1-10. PubMed ID: 1741009
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study.
    Kovac M; Kostanyan L; Mesaros N; Kuriyakose S; Varman M
    Hum Vaccin Immunother; 2018; 14(8):1977-1986. PubMed ID: 29630439
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Murphy TV; Slade BA; Broder KR; Kretsinger K; Tiwari T; Joyce PM; Iskander JK; Brown K; Moran JS;
    MMWR Recomm Rep; 2008 May; 57(RR-4):1-51. PubMed ID: 18509304
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Assessment of Tdap Vaccination Effectiveness in Adolescents in Integrated Health-Care Systems.
    Briere EC; Pondo T; Schmidt M; Skoff T; Shang N; Naleway A; Martin S; Jackson ML
    J Adolesc Health; 2018 Jun; 62(6):661-666. PubMed ID: 29551624
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Potential impact of acceleration of the pertussis vaccine primary series for infants.
    Shinall MC; Peters TR; Zhu Y; Chen Q; Poehling KA
    Pediatrics; 2008 Nov; 122(5):1021-6. PubMed ID: 18977982
    [TBL] [Abstract][Full Text] [Related]  

  • 76. An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine.
    Langley JM; Predy G; Guasparini R; Law B; Diaz-Mitoma F; Whitstitt P; Tapiero B; Dionne M; Tomovici A; Mills E; Halperin SA
    Vaccine; 2007 Jan; 25(6):1121-5. PubMed ID: 17045366
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model.
    Kwon HJ; Han SB; Kim BR; Kang KR; Huh DH; Choi GS; Ahn DH; Kang JH
    BMC Infect Dis; 2017 Apr; 17(1):247. PubMed ID: 28376777
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Whole-cell or acellular pertussis vaccination in infancy determines IgG subclass profiles to DTaP booster vaccination.
    van der Lee S; Sanders EAM; Berbers GAM; Buisman AM
    Vaccine; 2018 Jan; 36(2):220-226. PubMed ID: 29199041
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Comparison of acellular pertussis-tetanus-diphtheria vaccines and whole-cell pertussis-tetanus-diphtheria vaccines in infancy.
    Korkmaz HA; Aydin A; Unal B
    Paediatr Int Child Health; 2014 Aug; 34(3):198-202. PubMed ID: 24621240
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Spotlight on Tdap₅ vaccine (Covaxis®) as a single-booster immunization for the prevention of tetanus, diphtheria, and pertussis: in children (aged ≥4 years), adolescents, and adults.
    Scott LJ
    Paediatr Drugs; 2011 Apr; 13(2):133-5. PubMed ID: 21351814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.